Dysmenorrhea Treatment

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Medication, Surgery, Therapeutics), Distribution Channel, End-Users - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the dysmenorrhea treatment market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[189 Pages Report] The Dysmenorrhea Treatment Market size was estimated at USD 7.16 billion in 2023 and expected to reach USD 7.80 billion in 2024, at a CAGR 8.98% to reach USD 13.09 billion by 2030.

Dysmenorrhea Treatment Market
To learn more about this report, request a free PDF copy

Dysmenorrhea treatment refers to the therapeutic approaches for managing and alleviating the pain and discomfort associated with dysmenorrhea or menstrual cramps. Dysmenorrhea is a prevalent condition affecting a significant proportion of menstruating individuals, characterized by painful abdominal cramping that occurs during or before their menstrual periods. The treatments for treating dysmenorrhea aim to reduce the pain, improve quality of life, and minimize disruption to daily activities. Meanwhile, the rising awareness about women's reproductive health and government initiatives & programs supporting healthcare facilities for women contribute significantly to the expansion of dysmenorrhea-related treatments. The increasing number of clinical trials and huge investments by healthcare entities have also contributed to the large-scale dysmenorrhea treatments & diagnosis. However, the lack of reimbursement policies and strict regulations associated with the drugs for menstrual pains is a significant challenge for dysmenorrhea treatment providers. Companies are continuously working toward cutting treatment costs and investing in research activities for novel medications to remain competitive in this evolving market landscape. Moreover, the recent advancements in the therapy of dysmenorrhea and increasing adoption of wearable technology along with digital health services are frequently contributing to the future expansion of dysmenorrhea treatment. Additionally, harnessing data-driven insights using artificial intelligence and machine learning can also aid in developing personalized treatment plans and identifying patterns leading to new therapeutic interventions in dysmenorrhea treatments.

Dysmenorrhea Treatment Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management

Primary dysmenorrhea is experienced by up to 90% of women which is caused by uterine contractions and prostaglandin release during menstruation. The need for primary dysmenorrhea treatment mainly revolves around pain relief and management. Additional treatments include oral contraceptives that help regulate hormone levels, heat application to ease muscle tension, and lifestyle modifications such as exercise and stress reduction. Secondary dysmenorrhea is menstrual pain caused by an underlying medical condition, including endometriosis, pelvic inflammatory disease, or uterine fibroids. The need for secondary dysmenorrhea treatment focuses on addressing the root cause of the pain while also providing symptom relief. The treatment options for secondary dysmenorrhea vary depending on the specific medical condition. Endometriosis treatments may include hormonal therapy, surgical interventions such as laparoscopic surgery, and anti-inflammatory medications. The cases having pelvic inflammatory disease is the underlying cause of secondary dysmenorrhea, antibiotics are often prescribed to treat the infection.

Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea

Medications are often the first line of treatment for dysmenorrhea. Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, effectively reduce pain and inflammation associated with menstrual cramps. These medications are purchased over the counter or prescribed by a healthcare professional. Surgical intervention treatment is reserved for patients with severe dysmenorrhea caused by underlying conditions such as endometriosis or uterine fibroids. Laparoscopic surgery is minimally invasive and can effectively remove adhesions or fibroids causing the pain. In extreme cases, a hysterectomy, which is the removal of the uterus, may be performed to provide permanent relief from dysmenorrhea. Moreover, psychological interventions can be beneficial in addressing the emotional distress linked to dysmenorrhea and enhancing overall coping abilities. Most used psychological therapies include cognitive behavioral therapy (CBT), relaxation techniques (deep breathing, progressive muscle relaxation), and biofeedback (monitoring physiological processes such as heart rate variability, muscle tension, or skin temperature). Furthermore, various non-pharmacological approaches have gained popularity due to their potential benefits in managing dysmenorrhea symptoms without causing significant side effects. Few alternative treatments, including acupuncture, transcutaneous electrical nerve stimulation (TENS), aromatherapy, yoga, and dietary supplements, offer a variety of options for individuals seeking non-pharmacological methods to manage dysmenorrhea symptoms and provide comprehensive care options for patients experiencing menstrual pain.

Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches

In treating dysmenorrhea, hospital pharmacies are crucial in providing patients with immediate and appropriate medication. Hospital pharmacies often have a wide range of over-the-counter (OTC) and prescription medications to treat various types of dysmenorrhea, including nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, antispasmodics, and hormonal treatments, including oral contraceptives. Online pharmacies are increasingly popular for purchasing dysmenorrhea treatments due to their convenience, discreteness, and competitive pricing. Online platforms offer a variety of products, including traditional OTC medications and alternative remedies such as herbal supplements and heat patches. The preference for online pharmacies is higher among those seeking privacy or living in remote areas with limited access to physical retail outlets. Retail pharmacies remain an essential distribution channel for dysmenorrhea treatments as they offer easy access to medication without needing a prior appointment with a healthcare professional. These pharmacies stock various OTC medications, including ibuprofen, naproxen, and aspirin. Retail pharmacies cater to consumers preferring face-to-face interaction with pharmacists for personalized advice and recommendations.

End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective

In the homecare sector, end-users prefer easily accessible and cost-effective treatment options to manage dysmenorrhea symptoms. These include over-the-counter (OTC) medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, and naproxen, and natural remedies, including heat therapy and herbal supplements. Homecare also involves alternative therapies such as yoga, acupuncture, and massage that have shown promising results in alleviating menstrual pain. End-users prefer hospitals in need of more intensive care or advanced interventions for treating severe cases of dysmenorrhea. Surgical treatments may also be recommended in patients with underlying gynecological conditions contributing to severe dysmenorrhea symptoms. Endometriosis-related menstrual pain can be treated in laparoscopic surgery by specialized gynecological surgeons in hospitals. Specialty clinics cater to end-users seeking specialized care from healthcare professionals with expertise in women's health issues, such as gynecologists, reproductive endocrinologists, and pelvic pain specialists. These clinics offer personalized treatment plans, including prescription medications, hormonal therapy, physical therapy, or psychological counseling.

Regional Insights

In American countries, including the United States and Canada, a large percentage of the female population experiences menstrual cramps, including dysmenorrhea. These countries witness various efforts to research and develop effective treatments for this condition with greater awareness of women's health issues. European Union countries have advanced healthcare systems that prioritize women's health, leading to significant funding for research on dysmenorrhea treatment options. For instance, the European Medicines Agency (EMA) has approved various medications targeting menstrual pain relief across European countries. Furthermore, China, Japan, and India are key markets within the Asia-Pacific region for dysmenorrhea treatment due to their large populations of women experiencing menstrual pain. Traditional medicine plays a crucial role in addressing dysmenorrhea in these countries. Moreover, research initiatives in this region explore the efficacy of alternative therapies, such as acupuncture and moxibustion, in treating dysmenorrhea. In Japan, a mix of traditional and modern medical approaches is adopted to address women's health issues, with patented medications such as Loxoprofen being prescribed for menstrual pain relief. India has observed an increase in investment in menstrual hygiene management and access to affordable healthcare with its growing awareness about women's health issues. The need for effective dysmenorrhea treatments worldwide varies across regions based on cultural factors, healthcare infrastructure, and awareness about women's health issues. Innovations in research and development provide promising opportunities for advancements in dysmenorrhea treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dysmenorrhea Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dysmenorrhea Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea

    Mithra Pharmaceuticals, a Belgian biotech company, and Fuji Pharma have collaborated to submit a marketing approval application for ESTELLE in Japan. This collaboration with Fuji Pharma demonstrates Mithra's commitment to reshaping women's health and offering potential breakthroughs on a global scale. [Published On: 2023-10-26]

  • Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

    Chime Biologics and Hope Medicine Inc. announced their collaboration to develop and manufacture a first-in-class monoclonal antibody drug, HMI-115. Chime Biologics aimed to collaborate with strategic business partners to provide clinical value and benefit to patients to expedite the process of targeting patients with endometriosis and alopecia. [Published On: 2023-10-26]

  • Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan

    Mithra Biotech received a EUR 2.5 million payment for the submission of an application by its license holder, Fuji Pharma, for Japanese marketing approval of ESTELLE. This strategy aims to address dysmenorrhea, a medical condition characterized by abdominal pain, headaches, fatigue, nausea, loss of appetite, and depression during menstruation. The progress made by Mithra Biotech and Fuji Pharma in addressing dysmenorrhea demonstrates their commitment to improving women's health and well-being. [Published On: 2023-10-25]

Key Company Profiles

The report delves into recent significant developments in the Dysmenorrhea Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Abbott Laboratories, AbbVie Inc., Alfa Pharma GmbH, Alvogen, Inc., ASKA Pharmaceutical Co., Ltd., Bayer AG, Comforté Cream by PMS4PMS, LLC, Cora Life by LYV Life, Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Ferring B.V., Gedeon Richter Plc., GlaxoSmithKline PLC, Haleon PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., LGM Pharma, Livia by iPulse Medical Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Micro Labs Limited, Myoovi, Myovant Sciences by Sumitovant Biopharma, Inc., Novartis AG, Ovira, Perrigo Company PLC, Pfizer Inc., Rael, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dysmenorrhea Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Primary Dysmenorrhea
    • Secondary Dysmenorrhea
  • Treatment
    • Medication
      • Combined Oral Contraceptive Pills
      • Cox-2 Inhibitors
      • Non-Steroidal Anti-Inflammatory Drugs
      • Over-The-Counter Medications
      • Transdermal Glyceryl Trinitrate
    • Surgery
      • Hysterectomy
      • Intrauterine Device
      • Laparoscopic Uterosacral Nerve Ablation
      • Levonorgestrel Intrauterine System (LN-IUS)
      • Presacral Neurectomy
    • Therapeutics
      • Alternative Therapies
      • Psychological Therapies
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-Users
    • Homecare
    • Hospitals
    • Specialty Clinics

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Dysmenorrhea Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dysmenorrhea Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Dysmenorrhea Treatment Market?
  4. What is the market share of the leading vendors in the Dysmenorrhea Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Dysmenorrhea Treatment Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Dysmenorrhea Treatment Market, by Type
  7. Dysmenorrhea Treatment Market, by Treatment
  8. Dysmenorrhea Treatment Market, by Distribution Channel
  9. Dysmenorrhea Treatment Market, by End-Users
  10. Americas Dysmenorrhea Treatment Market
  11. Asia-Pacific Dysmenorrhea Treatment Market
  12. Europe, Middle East & Africa Dysmenorrhea Treatment Market
  13. Competitive Landscape
  14. Competitive Portfolio
  15. List of Figures [Total: 24]
  16. List of Tables [Total: 650]
  17. List of Companies Mentioned [Total: 36]
Ditching discomfort: Move toward digital and clinical dysmenorrhea treatment
March 10, 2024
Ditching discomfort: Move toward digital and clinical dysmenorrhea treatment
Dysmenorrhea awareness is mounting, and this has garnered the introduction of scientifically-backed medications, remedy programs, and relief products. Some of these treatments ensure each woman gets care that resounds with her own experience.

Around 4 out of 5 women encounter period pain at some age in their lifespan, from early teen years up to menopause. Although women experience discomfort during menstruation, especially on the first day, up to 10% of women experience severe pain enough to disrupt their daily lives.

This pain, medically called dysmenorrhea, can be low back and thigh pain, headache, nausea, diarrhea, or fatigue. Women worldwide have adapted to NSAIDS, acetaminophen, birth control pills, hormone treatment, dietary changes, vitamins, exercise, heat, or massage for treating this severe case, whether it be primary or secondary dysmenorrhea.

Countries such as Spain and Mexico have worked on providing menstrual leaves for dysmenorrhea patients. With advancements in medication and therapies backed by government awareness campaigns for their improved accessibility, now more women have solace from period pain attacks.

Besides, AI-powered care is the next-generation treatment for dysmenorrhea. In January 2024, MenstrEaze introduced an AI-powered Care Program and products to provide personalized wellness solutions for women struggling with menstrual cramps and PMS, naming it the "You Deserve Better Periods" initiative.

New clinical trials are also on the way for enhanced medications, and many are today available over the counter without prescriptions. As digital comfort remedies and physician-approved drugs get on track, it is about time that women find relief in their own bodies every day of the month.

Advances in Dysmenorrhea Treatment: A Look at Novel Drugs and Therapies
November 3, 2023
Advances in Dysmenorrhea Treatment: A Look at Novel Drugs and Therapies
Dysmenorrhea, or painful menstrual cramps, is one of the most common gynecological problems worldwide. It affects women of all ages and can significantly impact their quality of life. Fortunately, recent years have seen various advancements in treating dysmenorrhea, from traditional painkillers to novel drugs and therapies. This blog post explores the latest treatments available for dysmenorrhea, including their mechanism of action, efficacy, and safety.

Nonsteroidal Anti-inflammatory Drugs (NSAIDs):

NSAIDs are one of the most common treatments for dysmenorrhea, commonly used as painkillers. They work by inhibiting the production of prostaglandins, chemicals produced by the body in response to pain and inflammation. However, their long-term use is still a concern due to potential gastrointestinal and renal risks.

Hormonal Therapy:

Hormonal therapy is another option for women with dysmenorrhea. It involves using oral contraceptives, progestins, or GnRH analogs, which modify the menstrual cycle and reduce the amount of prostaglandins produced. Hormonal therapy has shown significant benefits in reducing the severity and duration of menstrual cramps, but contraindications, side effects, and individual health factors limit its use.

Calcitonin Gene-Related Peptide (CGRP) Inhibitors:

CGRP inhibitors are a new class of drugs that target the calcitonin gene-related peptide, a neuropeptide known to play a role in the pathophysiology of dysmenorrhea. These drugs block the CGRP receptor, reducing pain signals in the nervous system.

Transcranial Direct Current Stimulation (tDCS):

It involves the application of a weak electrical current to the brain, targeting areas involved in pain perception and modulation. Preliminary data suggests that tDCS can reduce the severity and duration of menstrual cramps, although its long-term effects and safety are still under investigation.

Mindfulness-Based Interventions:

Mindfulness-based interventions, including meditation, yoga, and cognitive-behavioral therapy, have also received attention as non-pharmacological treatments for dysmenorrhea. These interventions aim to improve the psychological and emotional well-being of women with dysmenorrhea, reducing the impact of pain on their daily activities.

The treatment of dysmenorrhea has come a long way, from relying solely on painkillers to incorporating novel drugs and therapies that target the underlying mechanisms of pain. While NSAIDs and hormonal therapy remain the mainstay of treatment, CGRP inhibitors, tDCS, and mindfulness-based interventions offer new options for women with dysmenorrhea, with varying degrees of efficacy and safety.

Frequently Asked Questions
  1. How big is the Dysmenorrhea Treatment Market?
    Ans. The Global Dysmenorrhea Treatment Market size was estimated at USD 7.16 billion in 2023 and expected to reach USD 7.80 billion in 2024.
  2. What is the Dysmenorrhea Treatment Market growth?
    Ans. The Global Dysmenorrhea Treatment Market to grow USD 13.09 billion by 2030, at a CAGR of 8.98%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.